Recursion Pharmaceuticals ( NASDAQ: RXRX ) announces the pricing of its underwritten public offering of 30,769,230 shares of its Class A common stock at $6.50 a share, for an expected gross proceeds of approximately $200 million. All the shares are to be sold by the company.
In addition, the company has granted the underwriters a 30-day option to purchase up to an additional 4,615,384 shares of its Class A common stock. The offering is expected to close on or about June 28, 2024. RXRX stock fell 15.
4% to $7.41 in premarket trade on Thursday. More on Recursion Pharmaceuticals Recursion Pharmaceuticals: More Of A TechBio Industrializing Drug Discovery Recursion Pharmaceuticals: Unprecedented Scale Recursion Pharmaceuticals: Catalysts Are Coming And Success Is A Must AI-discovered drugs have an 80%–90% success rate: study.
